References
- Bolland , K. and Whitehead , J. 2000 . Formal approaches to safety monitoring of clinical trials in life-threatening conditions . Stat. in Med. , 19 : 2899 – 2917 .
- Campbell , E. T. , Regan , S. , Gruen , R. L. , Ferris , T. G. , Sowmya , R. R. , Cleary , P. D. and Blumenthal , D. 2007 . Professionalism in medicine: Results of a national survey of physicians . Ann. Intern. Med. , 147 : 795 – 802 .
- 21 CFR 312.32(c) (2004).
- 21 CFR 50.24(a)(7)(iv) (2004).
- Clemens , F. , Elbourne , D. , Darbyshire , J. and Pocock , S. 2005 . DAMOCLES GROUP. Data monitoring in randomized controlled trials: surveys of recent practice and policies . Clin. Trials , 2 ( 1 ) : 22 – 33 .
- Collins , J. F. 2003 . Data and safety monitoring board issues raised in the VA Status Epilepticus Study . Controlled Clinical Trials , 24 ( 1 ) : 71 – 77 .
- Cummings , S. M. , Savitz , L. A. and Konrad , T. R. 2001 . Reported response rates to mailed physician questionnaires . Health Services Research , 35 : 1347 – 1355 .
- Dillman , D. 2000 . “ Mail and intent questionnaires ” . In The Tailored Design Method , 2nd , John Wiley .
- DeMets , D. L. , Friedman , L. and Fuberg , C. D. 2005 . Data Monitoring in Clinical Trials: A Case Studies Approach , New York : Springer Science Business Media .
- DeMets , D. L. , Pocock , S. J. and Julian , D.G. 1999 . The agonizing negative trend in monitoring of clinical trials . The Lancet , 354 : 1983 – 1988 .
- Dixon , D. O. and Lagakos , S. W. 2000 . Should data and safety monitoring boards share confidential interim data? . Controlled Clinical Trials , 21 ( 1 ) : 1 – 6 .
- Ellenberg , S. S. , Fleming , T. R. and DeMets , D. L. 2002 . Data Monitoring Committees in Clinical Trials: A Practical Perspective , London : John Wiley & Sons .
- Food and Drug Administration (FDA). (2006). Guidance for clinical trial sponsors. Establishment and operation of clinical trial data monitoring committees. March 2006 http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm127073.pdf (http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm127073.pdf)
- Food and Drug Administration (FDA). (2001). Center for Biologics Evaluation and Research. Open Public Meeting FDA Guidance on Clinical Trial Data Monitoring Committees. Nov. 27, 2001. Transcript available from FDA Web site at http://www.fda.gov (http://www.fda.gov)
- Kaplan , Gilpin, A. M. , Holbrook , J. T. , Jabs , D. A. Meinert , C. L. 2003 . Data and safety monitoring board deliberations resulting in the early termination of the monoclonal antibody cytomegalovirus Retinitis Trial . Controlled Clinical Trials , 24 ( 1 ) : 92 – 98 .
- NIH Guide. NIH Policy for Data and Safety Monitoring http://grants.nih.gov (http://grants.nih.gov) (Accessed: 10 June 1998 ).
- NIH Guide. Further Guidance on a Data and Safety Monitoring for Phase I and Phase II Trials. http://grants2.nih.gov (http://grants2.nih.gov) (Accessed: 5 June 2000 ).
- Slutsky , A. and Lavery , J. V. 2004 . Data safety and monitoring boards . New England Journal of Medicine , 350 : 1143 – 1147 .
- VanGeest , J. B. , Johnson , T. O. and Welch , V. 2007 . Methodologies for improving response rates in surveys of physicians . Eval. & Health Prof. , 30 : 303 – 321 .
- Whitehead , J. 1999 . On being the statistician on a data and safety monitoring board . Stat. in Med. , 18 : 3425 – 3434 .
- Whitehead , J. 2000 . Monitoring and evaluating clinical trials data . Intensive Care Med. , 26 : S84 – S 88 .
- Williams , D. W. and Louis , T. A. 2003 . DSMB case study: decision making when a similar clinical trial is stopped early . Controlled Clinical Trials , 24 ( 1 ) : 85 – 91 .